Vector

Quick links to important sections

Vector

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vector

What is Vector? (Valsartan)

Property Description
Active Ingredient Valsartan
Form Oral Tablet (Film-coated)
Pharmacological Class Angiotensin II Receptor Blocker (ARB)
General Purpose Antihypertensive agent
Origin Synthetic Compound

The medicine Vector is a prescription medicine intended for systemic treatment, containing the single active ingredient known as Valsartan. Chemically, Valsartan is a synthetic compound specifically developed for cardiovascular use and is formulated as an oral tablet for consistent oral administration. As a monotherapy, Vector is often a preferred starting point for adults beginning treatment for systemic hypertension where a single agent is required, a positioning supported by established clinical practice.

Vector belongs to the important pharmacological class of Angiotensin II Receptor Blockers (ARBs), which are established antihypertensive agents. These agents, often informally referred to as Sartans, are defined by their unique mechanism of action against the Renin-Angiotensin-Aldosterone System (RAAS). ARBs are a core component in managing circulatory conditions and are effective at lowering blood pressure. This essential function is clinically recognized for regulating the body's pressure system.

The general purpose of therapy involving Valsartan is to achieve a controlled and sustained reduction in blood pressure to mitigate risk factors associated with systemic hypertension. This primary benefit is rooted in the drug's core action of Angiotensin II blockade, a process that prevents a powerful hormone from causing blood vessels to constrict or tighten. By facilitating vasodilation (vessel widening), the medication relieves chronic strain on the heart and the entire circulatory system, supporting overall cardiovascular health. The use of ARBs reliably assists in maintaining vascular resistance, confirming the medicine’s primary role in supporting long-term circulatory well-being.

Regulatory References

  1. NIH/MedlinePlus: Valsartan Drug Information

What side effects are possible with Vector?

The medicine Vector (Valsartan) is associated with an officially documented profile of adverse reactions and safety constraints, classified by governmental regulatory authorities. These effects are formally categorized by frequency and the body system affected, providing a structured understanding of the risk profile.

Frequency-Classified Adverse Reactions

Adverse reactions are grouped based on their observed incidence rate, with Common effects occurring in at least 1 in 100 people. These frequently documented effects include dizziness, headache, fatigue, and viral infection. Uncommon reactions, occurring in fewer patients, include cough, vertigo, abdominal pain, and nausea.

System-Organ-Class Safety Groups

Regulatory documentation groups adverse effects by the affected physiological system. Documented reactions include those affecting the Nervous System (e.g., dizziness), Vascular System (e.g., hypotension), Gastrointestinal System (e.g., diarrhea), Renal and Urinary System (e.g., renal impairment), and the Immune System.

Serious Adverse Reactions and Safety Constraints

The official label lists several serious adverse reactions, including the potential for Angioedema (swelling of the face, lips, tongue, and throat) and Acute Renal Failure. Safety constraints for specific populations are also defined. The medicine is contraindicated for use during the second and third trimesters of pregnancy due to the documented risk of fetal injury and death. Caution and specific monitoring are required for patients with pre-existing conditions such as severe hepatic impairment or renal impairment.

Some effects, such as dizziness and hypotension, are explicitly noted in regulatory documents as being more likely to occur at the initiation of treatment or following a dose increase.

Overdose and Emergency Response

Overdose and When to Seek Help

Vector is associated with a risk of overdose, which is a medical emergency that can be fatal if not treated immediately. Overdose occurs when the opioid effect overwhelms the brain's ability to regulate breathing, causing respiratory depression.

Documented Overdose Symptoms

Symptoms of an opioid overdose often include:

  • Slow or shallow breathing or difficulty breathing (e.g., choking or gurgling sounds)
  • Unconsciousness or inability to awaken
  • Pinpoint pupils (the center part of the eye is very small)
  • Fingernails or lips turning blue or purple (a sign of oxygen deprivation)
  • Cold, clammy skin and a limp body

Emergency Actions and Immediate Medical Help

If an overdose is suspected, immediate medical attention is required.

  1. Call 911 (or local emergency services) immediately.
  2. Administer naloxone (if available) as an emergency measure to temporarily reverse the effects of the opioid. A second dose may be needed if the person does not respond within 2 to 3 minutes.
  3. Provide rescue breathing or CPR if the person is not breathing or is in cardiac arrest. Ventilatory support may be lifesaving on its own.

All individuals who have overdosed require transport to an emergency department for monitoring, even if they revive after naloxone administration. Due to naloxone's relatively short duration of action, symptoms may recur, necessitating observation for at least 4 hours after the last dose, or longer for those who took long-acting products.

Therapeutic Uses of Vector

Vector (Valsartan) is applied across therapeutic domains where additional symptomatic support is needed. It is relevant for easing symptoms related to physical discomfort and symptoms that create noticeable physiological strain. Its primary therapeutic uses are commonly applied across three related areas of cardiovascular health—managing Systemic Hypertension, supporting Chronic Heart Failure (HFrEF), and providing secondary prevention after a Myocardial Infarction.


Therapeutic Support and Benefit

The medication is commonly used to help with managing conditions where functional stability becomes affected and symptoms create noticeable physiological strain. The treatment may assist with managing symptoms related to heightened physiological activity; it supports patients during episodes of heightened discomfort and assists with maintaining functional stability. Vector may be part of symptomatic management applied across domains where additional symptomatic support is needed.


Quick Fact: Context of Symptom Management Vector is commonly applied when symptoms are linked to organ-specific functional stress, and supports general well-being during symptomatic phases.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Vector

The eligibility profile for Vector (Valsartan) is strictly defined by regulatory authorities to ensure safe use across patient populations.

Classification Population Status
Contraindicated Prohibited for patients with hypersensitivity to Valsartan or its components, and for women in the second and third trimesters of pregnancy. Use is also prohibited in patients with diabetes mellitus or renal impairment who are concurrently taking Aliskiren.
Not Recommended Use is not recommended in the first trimester of pregnancy and in breastfeeding/lactating women. Valsartan is generally not recommended for children under the age of 6 years.
Approved Use Adults (ge 18 years old) are approved for all labeled indications. Children and adolescents (mathbf6 to 17 years old) are approved only for the treatment of Hypertension.

Eligibility is conditional for certain patient groups. Patients with mild to moderate hepatic impairment or renal impairment may use Valsartan but require caution. Caution is also advised in cases of pre-existing volume or salt depletion before starting treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Vector (Valsartan) highlights specific combinations and substance types that affect systemic exposure or result in additive physiological effects, based on government regulatory documentation.

Formal Contraindications and Restrictions

The co-administration of Valsartan and Aliskiren is strictly contraindicated in patients with Diabetes Mellitus or with Renal Impairment (Glomerular Filtration Rate < 60 mL/min/1.73 m²). This prohibition addresses the potential risks associated with dual blockade of the Renin-Angiotensin System (RAS).

Pharmacodynamic and Exposure-Altering Interactions

Interacting Substance/Class Official Interaction Outcome Type of Interaction
Potassium-Sparing Diuretics/Supplements Increased risk of Hyperkalemia (high serum potassium). Pharmacodynamic
Non-Steroidal Anti-Inflammatory Agents (NSAIDs) Attenuation of antihypertensive effect and risk of renal function deterioration. Pharmacodynamic
Lithium Increased serum lithium concentrations and risk of toxicity. Exposure/Pharmacodynamic
Food Decreases rate and extent of systemic exposure (AUC reduced by approx 40%). Pharmacokinetic

Co-administration with other antihypertensive agents may result in additive blood pressure lowering effects. While food decreases systemic exposure, regulatory labels permit administration without regard to meals. The heightened risk of renal deterioration with NSAIDs is specifically noted for the elderly or volume-depleted populations.

Mechanism of Action

Targeted Gene Delivery to Liver Cells

Vector utilizes a specialized, non-replicating adeno-associated virus (AAV) vector as a delivery vehicle carrying the genetic blueprint for Factor IX. The vector specifically targets and binds to receptors on the surface of hepatocytes (liver cells), which leads to its internalization and the delivery of the therapeutic gene into the cell's nucleus. This interaction is essential for initiating the subsequent, endogenous production of the target protein.


Continuous Factor IX Synthesis and Coagulation Cascade Function

Once the genetic material is inside the hepatocyte nucleus, it acts as a template for the cell's machinery, triggering the continuous synthesis of functional Factor IX protein. The newly produced protein is processed and actively secreted by the hepatocyte into the bloodstream. The sustained presence of functional Factor IX protein in the plasma allows it to participate in the intrinsic and extrinsic pathways of the blood coagulation cascade. Factor IX functions as a component of the tenase complex, which facilitates the activation of Factor X. This mechanism enables the normal progression of the coagulation system, supporting the body's natural processes of hemostasis.

Dosage and Administration Information

How to Use Vector (Valsartan)


Vector (Valsartan) is an orally administered medication, available as film-coated tablets in multiple strengths (40 mg, 80 mg, 160 mg, and 320 mg) and as a compounded oral suspension for specific use in children. The medication may be taken with or without food, providing flexibility in the administration schedule.

The established usage pattern depends strictly on the condition being addressed, influencing both the daily dose and frequency:

Condition Typical Starting Dose Frequency Maintenance/Maximum Dose
Systemic Hypertension 80 mg or 160 mg Once daily Up to 320 mg once daily
Chronic Heart Failure 40 mg Twice daily Target 160 mg twice daily
Post-Myocardial Infarction 20 mg Twice daily Target 160 mg twice daily

For conditions requiring long-term control, such as heart failure and post-myocardial infarction, the regimen is structured as a time-dependent process. The starting dose is gradually titrated (increased) over several weeks—typically at intervals of at least two weeks—to achieve the maximal tolerated maintenance dose as established. The full blood pressure reduction effect is generally established within two weeks, with the maximal effect observed after four weeks of continuous treatment.

Specific instructions exist for certain populations. For instance, dosing for children aged 6 to 16 with hypertension is weight-based, and for patients with mild non-cholestatic hepatic impairment, the daily dose should not exceed 80 mg.

Recent Clinical Evidence

Research evidence / Overview of studies for Vector

The research base for Vector (Valsartan) relies on large-scale, long-term Randomized Controlled Trials (RCTs) across its main indications, primarily examining cardiovascular health outcomes and physiological strain.

Systemic Hypertension and Cardiac Events

For Systemic Hypertension, large RCTs monitored Blood Pressure (BP) changes and tracked major cardiovascular outcomes, including Stroke and Myocardial Infarction, typically following high-risk adults for several years. For patients with Chronic Heart Failure (HFrEF) and those at high risk following a Myocardial Infarction, research evaluated outcomes by tracking all-cause mortality and the frequency of heart failure-related hospitalization. In the post-MI research, studies explored comparing monotherapy versus combination therapy; no incremental change was observed in key long-term outcomes for patients receiving the combination versus monotherapy.

Evidence in Subgroups and Limitations

Research has explored outcomes in specific populations, including certain pediatric age groups for hypertension, though this data is more restricted in scope and duration than the large adult trials. For Heart Failure with Preserved Ejection Fraction (HFpEF), the evidence is limited to smaller, shorter-term trials that primarily measured surrogate markers like exercise capacity and neurohormonal biomarkers, rather than definitive, long-term clinical events. The follow-up durations for the HFpEF studies were typically limited to only a few months.

What is Still Uncertain About Vector’s Research Base

Research suggests that in some patient subgroups, such as those receiving triple-combination therapy for heart failure, the observed patterns varied, and these findings remain uncertain. Across the research base, comparative evidence is insufficient in certain contexts, and data for long-term outcomes are still emerging for several specific patient scenarios.

Key Studies & References Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) Trial: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine

Frequently Asked Questions (FAQ)

Common questions about Vector (FAQ)


Q: How does Vector differ from other common medicines for the same condition?

A: Vector belongs to the Angiotensin II Receptor Blocker (ARB) class of medicines. The official mechanism of action is blocking the effects of a hormone called Angiotensin II at its receptor site. This is described in regulatory documents as being distinct from another common class of blood pressure medicines, ACE inhibitors, which work by preventing the formation of that hormone.

Q: What should be done if I miss a dose of Vector?

A: If a dose is missed, the official patient information generally states that it can be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, official product information generally states that the missed dose is typically skipped, and the patient resumes the regular schedule. The labeling indicates that taking extra or double doses is not recommended.

Q: Does Vector interact with common over-the-counter pain relievers?

A: Yes, regulatory documents list Non-Steroidal Anti-Inflammatory Agents (NSAIDs), a class that includes many common over-the-counter pain relievers, as an interacting class. Official labeling suggests that this combination may lead to a decrease in the expected blood pressure lowering effect of Vector. It also notes an increased risk of kidney function issues, particularly for certain patient populations.

Q: What happens if Vector is taken with alcohol?

A: Official information indicates that consuming alcohol while using Vector may cause an additive effect in lowering blood pressure. The labeling indicates that this may increase the likelihood of certain reactions, such as dizziness or hypotension, especially at the start of treatment or following a change in dosage.

Q: Is Vector indicated for people with high blood pressure?

A: Vector is officially indicated for the management of high blood pressure and other circulatory conditions. While caution is advised because the medicine may cause hypotension (low blood pressure), official documents note this concern, particularly for those with low fluid or salt levels. Labeling suggests that monitoring certain parameters may be appropriate.

Q: Does Vector have a generic version available?

A: Yes, the active ingredient in Vector, which is Valsartan, is available as a generic drug product. Vector is the specific brand name for the medicine containing Valsartan.

Q: Is Vector used in long-term treatment?

A: Studies have examined the effects of the active ingredient over extended periods for its approved uses. Evidence indicates that the blood pressure-lowering effect was observed to be maintained in long-term follow-up studies, tracking patients for up to two years.

Q: Are there any foods or drinks to avoid while taking Vector?

A: Regulatory information notes that co-administration with food decreases the absorption of the medicine, though it may still be taken with or without food. Official labeling also advises caution with potassium-sparing diuretics and potassium supplements. This caution, according to regulatory documents, relates to the risk of high serum potassium (hyperkalemia) when used alongside potassium-containing products.

Q: Can Vector affect my mood or energy levels?

A: Studies and regulatory labeling report some adverse reactions affecting the central nervous system. These documented effects include fatigue and reports of dizziness. Under the neurologic and psychiatric system-organ class, reports of anxiety and insomnia (difficulty sleeping) have also been documented.

Q: What are the serious but rare side effects of Vector?

A: Official product information is required to document all adverse reactions. Serious effects that are rarely observed include Angioedema (swelling of the face, lips, or throat) and sudden, severe Acute Renal Failure. The frequency of all effects, including rare ones, is formally classified in regulatory documents.

Q: Is there a risk of dependency or withdrawal symptoms with Vector?

A: Vector is not associated with dependency. However, some antihypertensive medicines can be associated with a temporary rebound effect if treatment is abruptly discontinued.

Q: Is Vector appropriate for older adults?

A: Official regulatory labels indicate that, in general, no initial dosage adjustment is specifically required for older adults. However, studies show that older patients may have a higher overall systemic exposure to the medicine compared to younger adults.

Q: What if I'm taking herbal supplements—do they interact with Vector?

A: The official product labeling does not list specific interactions with individual herbal supplements. Regulatory documents state the importance of disclosing all products being used, including any vitamins or herbal supplements, to the prescriber. This is due to the potential for these products to affect blood pressure or potassium levels.

Q: Why does the packaging list so many potential side effects?

A: Regulatory agencies require that drug manufacturers list all adverse events reported across clinical trials and through post-marketing surveillance. This is intended to ensure comprehensive risk communication. The presence of a side effect on the label does not mean that every person taking the medicine will experience it.

Q: Does taking Vector require regular blood tests?

A: Due to the potential for the medicine to affect kidney function and increase serum potassium (known as hyperkalemia), the official label recommends monitoring certain clinical parameters. The official label suggests that periodic monitoring of parameters such as potassium levels and kidney function may be appropriate, particularly for certain patient populations.

Q: What if I feel like the drug isn't working after a few weeks?

A: Official information indicates that the maximum blood pressure reduction effect of the medicine is generally attained after about four continuous weeks of treatment. Clinical guidelines discuss the importance of remaining on the prescribed therapy for the duration needed to achieve the expected benefit.

Q: Does the time of day I take Vector matter?

A: The official documentation states the tablets can be taken with or without food. Although the effect of the medicine lasts for 24 hours, some limited clinical studies have suggested that the timing of a once-daily dose may affect blood pressure patterns throughout the day.

Q: How quickly does Vector leave the body after the last dose?

A: The official pharmacological profile of the active ingredient, Valsartan, defines its elimination rate by its terminal half-life. The half-life of Valsartan is approximately 6 hours, meaning it typically takes that amount of time for the plasma concentration of the drug to decrease by half.

Q: Is Vector a treatment or a cure for the condition it is used for?

A: Vector is officially indicated for the treatment and management of conditions such as high blood pressure and heart failure. It works by controlling the symptoms and risks associated with these long-term health issues; it is not described in official labeling as a cure.

Q: Does the effectiveness of Vector decrease over time?

A: Studies on long-term use suggest that the blood pressure-lowering effect appears to be maintained for at least two years. Official data on the product's stability also support the consistency of its effectiveness over time under recommended storage conditions.

Q: Can I take Vector if I have a history of liver problems?

A: Caution is advised for patients with existing mild to moderate hepatic impairment (liver problems) that are not due to bile flow obstruction. For these patients, some regulatory agencies have defined a limit for the maximum daily dose.

Q: Why do some people stop taking Vector?

A: In clinical trials, patient discontinuation of the medicine occurred for various reasons, including the occurrence of intolerable side effects like headache and dizziness. Discontinuation was also seen following serious adverse events, such as low blood pressure (hypotension) or a significant decline in renal function.

How should Vector be stored and disposed of?

How to Store and Dispose of Vector (Valsartan)

The storage of Vector (Valsartan) tablets must adhere to specific controlled conditions to maintain product integrity.


Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature between 20 C to 25 C (68 F to 77 F).
Container Keep the medicine in its original container, tightly closed, and protect from moisture.
Safety Keep this medication out of the sight and reach of children.

️ Disposal Instructions

Proper disposal is required to protect the environment. Do not flush the unused tablets down the toilet, and the product must not be thrown into wastewater. Unused or expired medication should be discarded through an official drug take-back program when available.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vector found in:

A-Z Index: